Molnupiravir reduced Covid-linked hospitalisation by over 65%: StudyThe Phase III trial results of Hetero's Movfor (Molnupiravir), presented at the Conference on Retroviruses and Opportunistic Infections (CR...
Phase III trials of COVID drug Movfor show positive results, says HeteroThe results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12...
Hetero gets DCGI nod to manufacture, market Molnupiravir capsulesUnder the licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries, fo...